key: cord-0428528-v18196of
authors: Fujigaki, H.; Yamamoto, Y.; Koseki, T.; Banno, S.; Ando, T.; Ito, H.; Fujita, T.; Naruse, H.; Hata, T.; Moriyama, S.; Takahashi, Y.; Suzuki, T.; Murakami, T.; Yoshida, Y.; Yagura, Y.; Oyamada, T.; Takemura, M.; Kondo, M.; Iwata, M.; Saito, K.
title: Antibody responses to BNT162b2 vaccination in Japan: Monitoring vaccine efficacy by measuring IgG antibodies against the receptor binding domain of SARS-CoV-2
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.19.21260728
sha: 40087f68359bdecd32efa7334f63b81b97cdc3ee
doc_id: 428528
cord_uid: v18196of

BACKGROUND: To fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), mass vaccination has begun in many countries. To investigate the usefulness of a serological assay to predict vaccine efficacy, we analyzed the levels of IgG, IgM, and IgA against the receptor binding domain (RBD) of SARS-CoV-2 in the sera from BNT162b2 vaccinated individuals in Japan. METHODS: This study included 219 individuals who received two doses of BNT162b2. The levels of IgG, IgM, and IgA against RBD were measured by enzyme-linked immunosorbent assay before and after the first and second vaccination, respectively. The relationship between antibody levels and several factors including age, gender, and hypertension were analyzed. Virus-neutralizing activity in sera was measured to determine the correlation with the levels of antibodies. A chemiluminescent enzyme immunoassay (CLEIA) method to measure IgG against RBD was developed and validated for the clinical setting. RESULTS: The levels of all antibody isotypes were increased after vaccination. Among them, RBD-IgG was dramatically increased after the second vaccination. The IgG levels in females were significantly higher than in males. There was a negative correlation between age and IgG levels in males. The IgG levels significantly correlated with the neutralizing activity. The CLEIA assay measuring IgG against RBD showed a reliable performance and a high correlation with neutralizing activity. CONCLUSIONS: Monitoring of IgG against RBD is a powerful tool to predict the efficacy of SARS-CoV-2 vaccination and provides useful information in considering a personalized vaccination strategy for COVID-19.

This study included 219 individuals who received two doses of BNT162b2. 59 The levels of IgG, IgM, and IgA against RBD were measured by enzyme-linked 60 immunosorbent assay before and after the first and second vaccination, respectively. 61 The relationship between antibody levels and several factors including age, gender, and 62 hypertension were analyzed. Virus-neutralizing activity in sera was measured to 63 determine the correlation with the levels of antibodies. A chemiluminescent enzyme 64 immunoassay (CLEIA) method to measure IgG against RBD was developed and 65 validated for the clinical setting.

The levels of all antibody isotypes were increased after vaccination. Among 67 them, RBD-IgG was dramatically increased after the second vaccination. The IgG levels 68 in females were significantly higher than in males. There was a negative correlation 69 between age and IgG levels in males. The IgG levels significantly correlated with the 70 neutralizing activity. The CLEIA assay measuring IgG against RBD showed a reliable 71 performance and a high correlation with neutralizing activity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. December 11 th , 2020, a mass vaccination campaign began throughout the world. 90 Now that it has been demonstrated that the COVID-19 vaccines can induce a 91 humoral response thereby protecting individuals from symptomatic COVID-19, several 92 studies attempted to use serological assays to detect antibody production following 93 COVID-19 vaccination (9-13). To monitor the efficacy of vaccines, antibody titer can be 94 used to predict protection against SARS-CoV-2, which is already done as a routine 95 laboratory testing for many viruses, such as measles morbillivirus, rubella virus, and 96 hepatitis virus. 97 There is consensus that serological assays are helpful for predicting vaccine 98 efficacy; however, a variety of antigens used to detect antibodies and a variety of 99 antibody isotypes measured in these assays may cause issues with interpreting the 100 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. 190 We utilized another laboratory test kit (18) for the Accuraseed automated CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. antibody titer of RBD-IgG, IgM and IgA were measured by ELISA assay. All antibody titer 219 increased after the first and second vaccinations compared with before the first 220 vaccination, but dramatically increased after the second vaccination (Fig. 1) . The IgG 221 titers in the serum of all subjects ranged between 0.0 and 1.8 U/mL with a mean of 0.1 ± 222 0.2 U/mL before the first vaccination, between 0.0 and 100.9 U/mL with a mean of 11.8 ± 223 12.8 U/mL after the first vaccination and between 17.2 and 762.4 U/mL with a mean of 224 246.6 ± 153.6 U/mL after the second vaccination (Fig. 1A) . The average titer after the 225 second vaccination increased more than 20 times from the average titer after the first 226 vaccination (p < 0.01). In serum after the second vaccination, IgM titers in all subjects 227 ranged between 0.7 and 146.8 U/mL with a mean of 8.7 ± 13.1 U/mL and IgA titers 228 ranged between 2.1 and 127.5 U/mL with a mean of 34.1 ± 21.5 U/mL ( Fig. 1B and C) . 229 The antibody titers showed differences between genders. Each antibody titter 230 was compared between males and females. The IgG titer after the second vaccination of 231 females was significantly higher compared with that of males (p < 0.05) (Fig. 1D) . The 232 average antibody titer was 263.6 ± 158.0 U/mL for females and was 209.9 ± 137.6 U/mL 233 for males. Previous data showed that age was also an important factor of antibody titer 234 after vaccination (9). Therefore, correlations were established between age and each 235 antibody titter. In males, age correlates negatively with RBD-IgG (r = −0.410) and IgM (r 236 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260728 doi: medRxiv preprint 13 = −0.283) ( Fig. 2A and B, upper panel) . In contrast, each antibody titter did not show a 237 correlation with age for females (Fig. 2, lower panel) . Several diseases, such as cancer, 238 chronic kidney disease, hypertension, and diabetes, have been reported to be 239 associated with the severity of COVID-19. The IgG titers of hypertensive subjects were 240 significantly decreased compared to control subjects in male, but there was no difference 241 in female (Fig. 3A) . Antibody titer did not show differences between those with allergies 242 and no medical treatment controls (Fig. 3B) . 243 For the protection against COVID-19 infection, whether the antibody exhibits (Fig. 4) . 250 Among the isotypes, IgG showed a higher correlation with neutralizing activity (r = 251 0.896). 252 A rapid and accurate method to monitor antibody titers is a useful tool to 253 investigate the efficacies of vaccination in clinical laboratories. Therefore, we developed 254 a new CLEIA method using a two-step sandwich method to measure anti-SARS-CoV-2 255 antibody with the Accuraseed automated immunoassay system. This method measured 256 antibody titers within about 10 minutes (Fig. S1) . To validate the CLEIA assay, the limit of 257 blank, limit of detection and limit of quantification, repeatability (intra-day precision) and 258 linearity within assay range were established (Fig. S2-S4 , Table S1-S3). To assess this 259 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260728 doi: medRxiv preprint 14 new method, we examined the relationship between RBD-IgG levels measured by ELISA 260 and that of the CLEIA assay. The correlation was determined between RBD-IgG levels 261 by ELISA and RBD-IgG levels by CLEIA assay (R = 0.979, y = 0.92x-0.27) (Fig. 5A) . 262 Furthermore, the levels of the RBD-IgG by CLEIA assay correlated with the 263 virus-neutralizing activity (r = 0.869) (Fig. 5B) . Increasing evidence suggests that The RBD-IgG levels after the second vaccination of males were significantly 298 lower compared with those of females (Fig. 1D) . Several studies suggest that there are 299 many differences between males and females with respect to the immune response to 300 SARS-CoV-2 infection and inflammatory diseases (21). Females generally produce 301 higher levels of antibodies which remain in the circulation longer. The activation of 302 immune cells is higher in females than males, and it correlates with the trigger of TLR7 303 and the production of interferon. Therefore, women with COVID-19 show a better 304 outcome than men with the infection (22). These studies support our findings that 305 females have a higher antibody-producing ability than males following the vaccination. 306 In the present study, elderly males had a lower RBD-IgG antibody-producing 307 ability than their younger counterparts ( Fig. 2A) . Previous data have shown that there are 308 age-related differences in antibody responses raised after BNT162b2 vaccination, in 309 particular, lower frequencies of neutralizing antibodies in the elderly group (12). These 310 data suggest that the vaccination is effective for all ages, but it is important to continue 311 preventive measures for COVID-19, especially in elderly males at least until more 312 longitudinal real-world data emerges. 313 Several diseases, such as cancer, chronic kidney disease, hypertension and 314 diabetes, have been reported to be associated with the severity of COVID-19. The 315 present results show that the antibody titers of hypertensive subjects in male were 316 significantly lower compared with control subjects, but there was no statistical difference 317 in females. Also, our analysis showed that there was no correlation between antibody 318 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. reported that age and gender were statistically associated with differences in antibody 320 response after vaccination, which is consistent with our results, whereas body mass 321 index and hypertension had no statistically significant association. Further studies are 322 needed to investigate what factors influence antibody responses from SARS-CoV-2 323 vaccination using a larger cohort. 324 We developed and validated a new method for measuring RBD-IgG using an 325 automated CLEIA method. RBD-IgG measured by Accuraseed is a rapid, accurate and 326 precise method that strongly correlates with neutralizing activity (Fig. 5, Fig. S2 -S5, 327 Tables S1-S3). Since monitoring antibody response that correlates with neutralizing 328 activity after SARS-CoV-2 vaccination is highly advisable for predicting protection 329 against SARS-CoV-2, this method may become a useful tool to monitor the efficacy of 330 vaccination in clinical laboratories. 331 In conclusion, this study demonstrated that IgG, IgM, and IgA antibodies against 332 RBD were produced after BNT162b2 vaccination in all subjects. Among these antibodies, 333 RBD-IgG correlated best with neutralizing activity. These results suggest that monitoring 334 of RBD-IgG is a powerful tool to predict efficacy of SARS-CoV-2 vaccination. The level of 335 RBD-IgG after the second vaccination was affected by gender and age, which provide 336 useful information to consider a personalized vaccination strategies for COVID-19.

Acknowledgments 339 We thank all the participants for participating in this study. We also thank the support 340 from medical technologists and clinical research coordinators at the Fujita Health 341 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260728 doi: medRxiv preprint

Coronavirus from Patients with Pneumonia in China

369 tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored 370 COVID-19 vaccine: a dose-escalation, open-label, non-randomised, 371 first-in-human trial

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell 375 responses

ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

A vaccine targeting the 385 RBD of the S protein of SARS-CoV-2 induces protective immunity

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

CC-BY-ND 4.0 International license and dynamics: a prospective, single-centre, longitudinal cohort study in 419 health-care workers

Reliability of serological tests for COVID-19: comparison of three 423 immunochromatography test kits for SARS-CoV-2 antibodies

Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes 427 in COVID-19 Patients

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Development of a New Chemiluminescent Enzyme Immunoassay Using a 435 Two-Step Sandwich Method for Measuring Aldosterone Concentrations

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Immunological memory to SARS-CoV-2 assessed for up to 8 months after 440 infection

The role of IgA in COVID-19

Sex differences in immune responses that underlie COVID-19 disease outcomes. 446

Coronavirus COV-19/SARS-CoV-2 affects women less than 449 men: clinical response to viral infection

the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260728 doi: medRxiv preprint